Cumberland Pharmaceuticals (CPIX) Liabilities from Discontinued Operations (2019 - 2020)
Cumberland Pharmaceuticals (CPIX) reported Liabilities from Discontinued Operations of 1247011.0 for Q1 2020, down 42.04% sequentially from 2151357.0 in Q4 2019.
Cumberland Pharmaceuticals (CPIX) Liabilities from Discontinued Operations (2019 - 2020) Analysis & Trends
Cumberland Pharmaceuticals (CPIX) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 1247011.0 in Q1 2020.
- For the quarter ending Q1 2020, Liabilities from Discontinued Operations changed N/A year-over-year to 1247011.0; the trailing twelve-month figure through Mar 2020 stood at 1247011.0 (changed N/A YoY), and the FY2019 full-year result was 2151357.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations retreated to 1247011.0 in Q1 2020, from 2151357.0 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 2151357.0 in Q4 2019 to a low of 1247011.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Cumberland Pharmaceuticals | 104.57 Mn | 93.23 Mn | 7.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 1.25 Mn |
| Mar 31, 2020 | 1.25 Mn |
| Dec 31, 2019 | 2.15 Mn |
| Dec 31, 2019 | 2.15 Mn |